Cytolon
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area.It is Cytolon's strategy to position the Company and its new service platform, CordMatch®, for a crossroad in regenerative medicine - the need for adult stem cell products that are tailored to the patient based on the matching of his histocompatibility antigens and genetic needs
Cytolon's experienced team is led by its founder, Thomas Klein. He is an internationally experienced business entrepreneur with a proven track record and more than twenty years of professional experience and twelve years as a founder and CEO of IT and Biotechnology companies.
| Type: | NORMAL |
| Address: | Alt Moabit 90b, 10559 Berlin |
| Website: | www.cytolon.com |
| Phone: | +49 (0) 30 800 978 30 |
| Email: | info@cytolon.com |